Algernon Pharmaceuticals Inc. (OTCQB: $AGNPF) is pleased to announce that it has received positive feedback from the U.S. FDA regarding the Company's plans to conduct a phase 2 COVID-19 clinical trial using its repurposed drug NP-120 (Ifenprodil). $MSFT $GLW $TMUS $DIS $DISH $HD